Limits...
Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus

SUVmax of 18F-FDG and 18F-Alfatide II PET in different categories of bone metastases.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4508500&req=5

Figure 4: SUVmax of 18F-FDG and 18F-Alfatide II PET in different categories of bone metastases.

Mentions: Both tracers showed relatively large variance in tracer uptake in bone lesions with a range from 0.6 to 11.91 for 18F-FDG and 0.95 to 13.87 for 18F-Alfatide II (Figure 4). In all groups, no significant difference was found between 18F-FDG and 18F-Alfatide II (P > 0.05 for all comparisons). Both tracers showed significantly lower accumulation in osteoblastic lesions than that in osteolytic and mixed lesions (P < 0.001 for all comparisons). SUVmax of 18F-FDG in osteoblastic lesions was also significantly lower than that in bone marrow metastases (P < 0.05). However, there was no significant difference of 18F-Alfatide II SUVmax in osteoblastic lesions and bone marrow metastases.


Pilot Prospective Evaluation of (18)F-Alfatide II for Detection of Skeletal Metastases.

Mi B, Yu C, Pan D, Yang M, Wan W, Niu G, Chen X - Theranostics (2015)

SUVmax of 18F-FDG and 18F-Alfatide II PET in different categories of bone metastases.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4508500&req=5

Figure 4: SUVmax of 18F-FDG and 18F-Alfatide II PET in different categories of bone metastases.
Mentions: Both tracers showed relatively large variance in tracer uptake in bone lesions with a range from 0.6 to 11.91 for 18F-FDG and 0.95 to 13.87 for 18F-Alfatide II (Figure 4). In all groups, no significant difference was found between 18F-FDG and 18F-Alfatide II (P > 0.05 for all comparisons). Both tracers showed significantly lower accumulation in osteoblastic lesions than that in osteolytic and mixed lesions (P < 0.001 for all comparisons). SUVmax of 18F-FDG in osteoblastic lesions was also significantly lower than that in bone marrow metastases (P < 0.05). However, there was no significant difference of 18F-Alfatide II SUVmax in osteoblastic lesions and bone marrow metastases.

Bottom Line: Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET.In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions.This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

View Article: PubMed Central - PubMed

Affiliation: 1. Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University (Wuxi 4th People's Hospital), Wuxi, China.

ABSTRACT
This pilot prospective evaluation study is to verify the efficiency of (18)F-Alfatide II, a specific PET imaging agent for integrin αvβ3, in detecting bone metastasis in human, with comparison to (18)F-FDG PET. Thirty recruited patients underwent (18)F-FDG and (18)F-alfatide II PET/CT successively within days. The final diagnosis of bone lesions was established based on the comprehensive assessment of all available data and clinical follow-up, which fall into four groups: osteolytic, osteoblastic, mixed and bone marrow. Visual analysis and quantification of SUVmax were performed to compare the detection sensitivity of (18)F-Alfatide II and (18)F-FDG PET. Eleven patients were found to have a total of 126 bone metastasis lesions. (18)F-Alfatide II PET can detect the bone metastatic lesions with good contrast and higher sensitivity (positive rate of 92%) than (18)F-FDG PET (77%). Especially, (18)F-Alfatide II PET showed superiority to (18)F-FDG PET in detecting osteoblastic (70% vs. 53%) and bone marrow metastatic lesions (98% vs. 77%). In conclusion, (18)F-Alfatide II PET/CT can be used to detect skeletal and bone marrow metastases, with nearly 100% sensitivity in osteolytic, mixed and bone marrow lesions. The sensitivity of (18)F-Alfatide II PET/CT in osteoblastic metastases is relatively low but still significantly higher than that of (18)F-FDG PET/CT. This pilot clinical study warrants the further application of (18)F-Alfatide II PET/CT in metastatic lesion detection, patient management and drug therapy response monitoring.

No MeSH data available.


Related in: MedlinePlus